Patritumab

DB12090InvestigationalProtein Based Therapies

Patritumab has been used in trials studying the treatment of LUNG CANCER, Solid Tumors, Neoplasms by Site, Head and Neck Neoplasms, and Non-small Cell Lung Cancer, among others.

Mechanism: Pharmacologically active on Receptor tyrosine-protein kinase erbB-3
Curator reviewed
Code names: AMG-888 · U3-1287

Resolves to

Compound

UNII86780VJI1QCAS1262787-83-6

Targets

P21860ERBB3

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

381Drug interactionsStructured to mechanism, not free text

12Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Patritumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account